IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY
Combined antiretroviral therapy (cART) provides HIV-infected people life expectancy comparable with HIV-uninfected people and turns the disease into a manageable chronic condition necessitating the need for innovative inflammatory markers. Our purpose was to determine the correlation between IL-6,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Peytchinski Publishing
2023-09-01
|
| Series: | Journal of IMAB |
| Subjects: | |
| Online Access: | https://www.journal-imab-bg.org/issues-2023/issue3/2023vol29-issue3-5099-5102.pdf |
| _version_ | 1797688110217166848 |
|---|---|
| author | Ivaylo Pakov Adelaida Ruseva Irena Gencheva Tsetsa Doichinova Milena Karcheva Kalina Terzieva Lyudmila Pakova Biserka Vasileva Galya Gancheva |
| author_facet | Ivaylo Pakov Adelaida Ruseva Irena Gencheva Tsetsa Doichinova Milena Karcheva Kalina Terzieva Lyudmila Pakova Biserka Vasileva Galya Gancheva |
| author_sort | Ivaylo Pakov |
| collection | DOAJ |
| description | Combined antiretroviral therapy (cART) provides HIV-infected people life expectancy comparable with HIV-uninfected people and turns the disease into a manageable chronic condition necessitating the need for innovative inflammatory markers.
Our purpose was to determine the correlation between IL-6, D-dimer and high-sensitivity C-reactive protein (hsCRP) levels among HIV-infected and the presence of chronic inflammation during general and immunological aging and drug exposure.
Material and methods: Comparative prospective study was conducted at 37 HIV-positive persons from the Center for Monitoring and Treatment of HIV-positive Patients at the Clinic for Infectious Diseases, UMBAL “Dr. G. Stranski” – Pleven (target group) and 18 HIV-negative individuals from outpatient practice (control group), aged ≥18 years.
Results: The median age of seropositive persons was 40 years (24÷70 years), of the control group – 51 years (29÷72 years); 78% of the target group and 61% of the controls are men. The average duration of ART is 4 years (1÷9 years). The study of specified biomarkers in the target group found increased IL-6 in 8.11% of patients (mean 3.67±1.86 pg/mL; range 1.5÷8.62; 95% CI 3.11-5.02), increased D-dimer in 8.11% (mean 0.37±0.28 µg/mL; 0.21÷1.96; 95% CI 0.3691-0.37459) and increased hsCRP in 10.81% (mean 2.10±1.99 µg/mL; 0.19÷7.0; 95% CI 1.89-2.31). In the control group IL-6 was not increased (mean 2.75±1.67 pg/mL; 1.5÷6.91), D-dimer was increased in 16.67% (mean 0.37±0.17 µg/mL; 0.09÷0.8) and increased hsCRP – in 5.56% (mean 1.76±1.75 µg/mL; 0.19÷5.66). Il-6 was significantly higher in the target group.
Conclusion: The implementation of sensitive biomarkers is crucial in the general diagnostic-therapeutic approach in aging with HIV. |
| first_indexed | 2024-03-12T01:27:16Z |
| format | Article |
| id | doaj.art-6f5f944890c84feeade77cedcc6ac199 |
| institution | Directory Open Access Journal |
| issn | 1312-773X |
| language | English |
| last_indexed | 2024-03-12T01:27:16Z |
| publishDate | 2023-09-01 |
| publisher | Peytchinski Publishing |
| record_format | Article |
| series | Journal of IMAB |
| spelling | doaj.art-6f5f944890c84feeade77cedcc6ac1992023-09-12T15:19:49ZengPeytchinski PublishingJournal of IMAB1312-773X2023-09-012935099510210.5272/jimab.2023293.5099IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDYIvaylo Pakov0https://orcid.org/0000-0002-0030-7876Adelaida Ruseva1https://orcid.org/0000-0002-3944-8828Irena Gencheva2https://orcid.org/0000-0003-4239-2703Tsetsa Doichinova3https://orcid.org/0000-0002-7932-9487Milena Karcheva4https://orcid.org/0000-0003-3562-094XKalina Terzieva5https://orcid.org/0000-0002-3014-5679Lyudmila Pakova6Biserka Vasileva7https://orcid.org/0000-0002-2738-6965Galya Gancheva8https://orcid.org/0000-0003-3213-4372Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven, Bulgaria.Department of Clinical Immunology, Allergology and Clinical Laboratory, Faculty of Health Care, Medical University – Pleven, Bulgaria.Department of Clinical Immunology, Allergology and Clinical Laboratory, Faculty of Health Care, Medical University – Pleven, Bulgaria.Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven, Bulgaria.Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven, Bulgaria.Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven, Bulgaria.Group Practice Outpatient Clinic for Primary Medical Care – “Dr Elina Stefanova and Dr Lyudmila Pakova” – OOD, Pleven, Bulgaria.Department of Therapeutic Care, Faculty of Health Care, Medical University – Pleven, Bulgaria.Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven, Bulgaria.Combined antiretroviral therapy (cART) provides HIV-infected people life expectancy comparable with HIV-uninfected people and turns the disease into a manageable chronic condition necessitating the need for innovative inflammatory markers. Our purpose was to determine the correlation between IL-6, D-dimer and high-sensitivity C-reactive protein (hsCRP) levels among HIV-infected and the presence of chronic inflammation during general and immunological aging and drug exposure. Material and methods: Comparative prospective study was conducted at 37 HIV-positive persons from the Center for Monitoring and Treatment of HIV-positive Patients at the Clinic for Infectious Diseases, UMBAL “Dr. G. Stranski” – Pleven (target group) and 18 HIV-negative individuals from outpatient practice (control group), aged ≥18 years. Results: The median age of seropositive persons was 40 years (24÷70 years), of the control group – 51 years (29÷72 years); 78% of the target group and 61% of the controls are men. The average duration of ART is 4 years (1÷9 years). The study of specified biomarkers in the target group found increased IL-6 in 8.11% of patients (mean 3.67±1.86 pg/mL; range 1.5÷8.62; 95% CI 3.11-5.02), increased D-dimer in 8.11% (mean 0.37±0.28 µg/mL; 0.21÷1.96; 95% CI 0.3691-0.37459) and increased hsCRP in 10.81% (mean 2.10±1.99 µg/mL; 0.19÷7.0; 95% CI 1.89-2.31). In the control group IL-6 was not increased (mean 2.75±1.67 pg/mL; 1.5÷6.91), D-dimer was increased in 16.67% (mean 0.37±0.17 µg/mL; 0.09÷0.8) and increased hsCRP – in 5.56% (mean 1.76±1.75 µg/mL; 0.19÷5.66). Il-6 was significantly higher in the target group. Conclusion: The implementation of sensitive biomarkers is crucial in the general diagnostic-therapeutic approach in aging with HIV.https://www.journal-imab-bg.org/issues-2023/issue3/2023vol29-issue3-5099-5102.pdfil-6d-dimerhscrpchronic inflammationhiv |
| spellingShingle | Ivaylo Pakov Adelaida Ruseva Irena Gencheva Tsetsa Doichinova Milena Karcheva Kalina Terzieva Lyudmila Pakova Biserka Vasileva Galya Gancheva IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY Journal of IMAB il-6 d-dimer hscrp chronic inflammation hiv |
| title | IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY |
| title_full | IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY |
| title_fullStr | IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY |
| title_full_unstemmed | IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY |
| title_short | IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY |
| title_sort | il 6 d dimer and high sensitivity c reactive protein in hiv infection preliminary study |
| topic | il-6 d-dimer hscrp chronic inflammation hiv |
| url | https://www.journal-imab-bg.org/issues-2023/issue3/2023vol29-issue3-5099-5102.pdf |
| work_keys_str_mv | AT ivaylopakov il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT adelaidaruseva il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT irenagencheva il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT tsetsadoichinova il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT milenakarcheva il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT kalinaterzieva il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT lyudmilapakova il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT biserkavasileva il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy AT galyagancheva il6ddimerandhighsensitivitycreactiveproteininhivinfectionpreliminarystudy |